To investigate the effect of sodium glucose cotransporter 2 inhibitor (SGLT-2I) on bone turnover markers in overweight and obese patients with type 2 diabetes mellitus. Methods: according to the criteria of selection and exclusion, 42 patients with overweight and obese type 2 diabetes (BMI≥25kg/m2) were selected from October 2019 to May 2020. The patients were randomly divided into experimental group and control group, there were 18 cases in the experimental group and 24 cases in the control group. The experimental group was treated with SGLT-2I, and other oral hypoglycemic agents (or insulin) were added according to the blood glucose situation. The control group received oral hypoglycemic agents (non-SGLT-2I) and/or insulin and/or glucagon-like peptide-1 receptor agonist (GLP-1 RA). Every 28 days of follow-up, medication regimen was adjusted according to blood glucose and adverse reactions of patients. Fasting venous serum of the patients was collected at the beginning and again 24 weeks later and the levels of PINP and β-CTX were detected uniformly. SPSS 21.0 was used to compare the changes of clinical indexes before and after the treatment. Results: 1. In the experimental group, PINP, HbA1c, FPG and BMI decreased (p<0.05). 2. In the control group, HbA1c, FPG and PINP decreased (p<0.05). 3. Comparison between groups after 24 weeks of treatment: there was significant difference in BMI (p<0.05).
Nonalcoholic fatty liver disease (NAFLD) is a prevalent chronic liver condition with limited treatment options. Inflammation caused by metabolic disturbances plays a significant role in NAFLD development. Stimulator of interferon gene (STING), a critical regulator of innate immunity, induces the production of interferons and other pro-inflammatory factors by recognizing cytoplasmic DNA to defend against pathogen infection. The STING-mediated signaling pathway appears to play a vital role in hepatic inflammation, metabolic disorders, and even carcinogenesis. Promisingly, pharmacological interventions targeting STING have shown improvements in the pathological state of NAFLD. Macrophages, dendritic cells, natural killer cells, and T cell pathways regulated by STING present potential novel druggable targets for NAFLD treatment. Further research and development in this area may offer new therapeutic options for managing NAFLD effectively.
近期中华医学会杂志社学术期刊出版平台在后台监测到部分用户使用虚假的手机号和Email地址注册账号,这些账号的投稿IP地址与作者所在单位所属行政区域严重偏离,涉嫌第三方机构代写代投.此类行为属于严重的学术不端,我们已将排查到的稿件信息通报各编辑部,杂志社新媒体部也将对此类账号做封禁处理,相关稿件一律做退稿处理.
1 Banting奖及杰出科学成就奖 2023年的美国糖尿病协会(ADA)Banting奖授予慕尼黑工业大学的亚历山大·冯·洪堡教席教授,慕尼黑亥姆霍兹公司首席执行官,德国亥姆霍兹公司协会副主席Matthias H.Tschöp教授,以表彰他在糖尿病和肥胖研究领域取得的开创性发现.Matthias H.Tschöp教授于1993年开始在慕尼黑大学医学院担任医学科学家(physician-scientist),在那里他遇到了不少与肥胖及其并发症作斗争的患者,当时肥胖还没有任何合适的治疗方案.
儿童Graves病(GD)相对少见,目前临床上对其管理尚未统一规范化,治疗选择上仍存在争议.2022年欧洲甲状腺学会发布了《儿童Graves病管理指南》,对儿童GD的临床特点、诊断和治疗等进行了全面讨论,并与成人GD相比较,为临床医生提供了详细、可靠的指导.熟悉该指南中给出的诊断、循证治疗建议等对临床上儿童GD的规范化管理具有现实意义.
